UC San Diego Health Moores Cancer Center | Strategic Alliance Partners

An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.

William B. Pearse, MD, discusses the current and future roles of BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Michael Choi, MD, expands on significant advancements and treatment considerations in hematologic malignancies.

Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.

Michael Choi, MD, discusses subsequent treatments for patients with relapsed/refractory CLL who progressed on a prior covalent BTK inhibitor.

Michael Choi, MD, discusses several key considerations for the treatment of chronic lymphocytic leukemia.

Michael Choi, MD, discusses key differences between BTK degraders & BTK inhibitors in the management of relapsed/refractory chronic lymphocytic leukemia.

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

Kathryn A. Gold, MD, discusses the benefit of targeted therapies in patients with mutated lung cancers.

Sandip P. Patel, MD, discusses the exploration of sacituzumab govitecan in the EVOKE-01 and EVOKE-02 trials in NSCLC and expands on future treatment directions with the agent in this patient population.

A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.

Lyudmila A. Bazhenova, MD, expanded on key considerations when navigating the use of perioperative immunotherapy for patients with or without oncogenically-driven lung cancers, the importance of multidisciplinary collaboration when deciding on a treatment plan, and the need for increased and earlier implementation of biomarker testing in all patients with lung cancer.

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss clinical trials evaluating the use of patritumab deruxtecan in patients with non–small cell lung cancer and remaining unmet needs.

Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

Experts on lung cancer review key data from the HERTHENA-Lung01 study investigating patritumab deruxtecan (HER3-DXd) in patients with advanced EGFR-mutated NSCLC.

A medical oncologist discusses the role of HER3 in the treatment of non–small cell lung cancer and provides an overview of the HERTHENA-Lung01 clinical trial.

Expert perspectives on unmet needs and therapies available for patients with EGFR-mutated non–small cell lung cancer.

Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy.

Sandip P. Patel, MD, discusses treatment options available for patients with EGFR-mutated NSCLC who progress on EGFR TKIs and platinum-based chemotherapy.

Medical oncologists specializing in lung cancer give an overview of the current treatment landscape for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Sandip P. Patel, MD, reviews data from the preliminary results of the EVOKE-02 study investigating sacituzumab govitecan plus pembrolizumab in first-line metastatic non–small cell lung cancer.

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.